CCSG - Cancer Prevention

Medicine & Life Sciences

1. Neoplasms 100%
2. Palliative Care 71%
3. Prostatic Neoplasms 60%
4. Rheumatoid Arthritis 53%
5. Quality of Life 41%
6. Pain 36%
7. Arachidonate 15-Lipoxygenase 36%
8. Breast Neoplasms 33%
9. Lipoxygenase 32%
10. Fatigue 30%
11. Systematic Reviews 30%
12. Therapeutics 30%
13. Randomized Controlled Trials 30%
14. Decision Support Techniques 29%
15. Radiotherapy 25%
16. Survival 24%
17. Rheumatology 23%
18. Confidence Intervals 23%
19. Symptom Assessment 23%
20. Early Detection of Cancer 22%
21. Knee Osteoarthritis 22%
22. Drug Therapy 21%
23. Health 20%
24. oleandrin 19%
25. Depression 19%
26. Odds Ratio 19%
27. Physicians 18%
28. Decision Making 18%
29. Radiation 17%
30. Ambulatory Care 16%
31. Delirium 16%
32. Referral and Consultation 16%
33. Cost-Benefit Analysis 16%
34. Hispanic Americans 15%
35. Costs and Cost Analysis 15%
36. Acupuncture 15%
37. Dinoprostone 15%
38. Cohort Studies 15%
39. Communication 15%
40. Breast 15%
41. Knee Replacement Arthroplasties 14%
42. Primary Health Care 14%
43. Opioid Analgesics 14%
44. Cyclooxygenase 2 14%
45. Peroxisome Proliferator-Activated Receptors 14%
46. Carcinogenesis 14%
47. Prostatectomy 13%
48. Placebos 13%
49. Sleep 13%
50. Osteoarthritis 13%
51. Anxiety 12%
52. Lung Neoplasms 12%
53. Health Care Outcome Assessment 12%
54. Brachytherapy 12%
55. Renal Cell Carcinoma 12%
56. Complementary Therapies 12%
57. Education 12%
58. Cancer Pain 12%
59. Meta-Analysis 12%
60. Antirheumatic Agents 12%
61. Prostate 12%
62. PBI-05204 11%
63. Methotrexate 11%
64. Prostate-Specific Antigen 11%
65. Caregivers 11%
66. Patient Preference 11%
67. Population 11%
68. Colorectal Neoplasms 11%
69. Clinical Trials 11%
70. Systemic Scleroderma 11%
71. Yoga 11%
72. Nerium 11%
73. Arthritis 10%
74. Arachidonic Acid 10%
75. Cachexia 10%
76. Spirituality 10%
77. Colonic Neoplasms 10%
78. Shared Decision Making 10%
79. Prospective Studies 10%
80. 15-hydroxyprostaglandin dehydrogenase 10%
81. prostaglandin E3 10%
82. Cardiac Glycosides 9%
83. Hip Osteoarthritis 9%
84. Apoptosis 9%
85. Social Support 9%
86. Uterine Cervical Neoplasms 9%
87. Economics 9%
88. Cancer Survivors 9%
89. Growth 9%
90. Watchful Waiting 9%
91. Osteoporosis 9%
92. Celecoxib 9%
93. Peripheral Arterial Disease 9%
94. huachansu 8%
95. Social Adjustment 8%
96. Chemoprevention 8%
97. Melanoma 8%
98. Integrative Oncology 8%
99. 13-hydroxy-9,11-octadecadienoic acid 8%
100. Delivery of Health Care 8%